JMP Securities Downgrades Arbutus Biopharma (ABUS) to Market Perform
Tweet
Share
E-mailGet Alerts ABUS Hot Sheet
Price: $4.67 +1.97%
Rating Summary:
7 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
7 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
JMP Securities analyst Liisa Bayko downgraded Arbutus Biopharma (NASDAQ: ABUS) from Market Outperform to Market Perform.
For an analyst ratings summary and ratings history on Arbutus Biopharma click here. For more ratings news on Arbutus Biopharma click here.
Shares of Arbutus Biopharma closed at $9.09 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- RBC Capital Downgrades Accelerant Holdings (ARX) to Sector Perform
- Barclays Downgrades Murphy Oil Corp. (MUR) to Underweight
Create E-mail Alert Related Categories
DowngradesRelated Entities
JMP SecuritiesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
